Baicalin Enhanced Oral Bioavailability of Sorafenib in Rats by Inducing Intestine Absorption
Background: Sorafenib (SOR) is an oral, potent, selective, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) used as the first-line therapy for advanced hepatocellular carcinoma (HCC). Baicalin (BG) is used as adjuvant therapy for hepatitis, which accounts for the le...
Guardado en:
Autores principales: | Jingyao Wei, Ruijuan Liu, Jiali Zhang, Shuaibing Liu, Dan Yan, Xueqian Wen, Xin Tian |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/4a48cab5eb4c44fbbdb5dd4acb8b1158 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
DETERMINATION OF CHLOROGENIC ACID, BAICALIN AND FORSYTHIN IN SHUANGHUANGLIAN PREPARATIONS BY HPLC-DAD
por: YANG,LI, et al.
Publicado: (2012) -
Biocompatible nanoemulsions based on hemp oil and less surfactants for oral delivery of baicalein with enhanced bioavailability
por: Yin J, et al.
Publicado: (2017) -
MiRNA-200b reverses drug resistance of hepatocellular carcinoma HepG2 cells to sorafenib and its underlying mechanism
por: DENG Yong, et al.
Publicado: (2021) -
Baicalin suppresses autophagy-dependent ferroptosis in early brain injury after subarachnoid hemorrhage
por: Bao Zheng, et al.
Publicado: (2021) -
Preparation, Characterization and in vivo Study of Borneol-Baicalin-Liposomes for Treatment of Cerebral Ischemia-Reperfusion Injury
por: Zhang Y, et al.
Publicado: (2020)